Roquette expands its business horizon in pharmaceutical excipients market
Date: 2017-06-23   Author: Satarupa De  Category: #news

Roquette, a global supplier of plant based innovative pharmaceutical ingredients has recently announced its strategic acquisition of the renowned Brazilian tablet maker, Itacel, which is essentially a subdivision of the well-known excipients manufacturer, Blanver. This strategic investment will extend Roquette’s penetration in the regional landscape of Latin America, since Itacel, in the present scenario is a front runner in Latin America’s food excipients and pharmaceutical markets. With this acquisition, Roquette will have the opportunity to establish a strong customer base across this belt, state industry analysts.

Founded in 1933, Roquette, the France rooted firm, presently supplies a range of plant-based natural food supplements and reportedly has a yearly turnover of more than USD 2 billion. Itacel, on the other hand, headquartered in Brazil, has already gained an international popularity in the pharmaceutical industry with its novel product offering that is used for drug formulations. Indeed, the acquisition is not only slated to mark the entry of a new competitor in the pharmaceutical excipients market, but is also forecast to allow Roquette enhance its contribution toward the food, health, and nutrition sectors. As per reliable reports, Itacel’s parent company Blanver is now interested in establishing two other business forums - active pharmaceutical ingredients and medicines, which seems to be the sole cause of divesting its excipients business.

Subject to the customary conditions in terms of commercial support, industrial assets, technical know-how, and product portfolio enrichment, the union of these two well-established firms is expected to simultaneously profit one another.  As stated by a higher official, through this strategic alliance, Roquette will introduce its expertise in the business that would further enrich Itacel’s long held cellulose based infrastructure and assets. The newly joint business model is expected to establish a better customer reach in the excipients market, addressing the future needs through more innovative solutions.

This collaborative approach also marks a milestone in the global pharmaceutical industry. Blanver’s domination in the excipients market across Latin America and Brazil will add a significant benefit to Roquette’s innovative product manufacturing capabilities, infrastructural asset, and commercial network. In a way, Roquette is on its way to expand its business in other emerging markets as well. Experts state that a robust growth forecast in global pharmaceutical excipients market in the coming few years will further push the business development. In addition, this strategic investment is expected to address the needs of the rapidly emerging nutraceutical and pharmaceutical sectors.



About Author


Satarupa De

Satarupa De

Satarupa currently works as a associate content writer at AlgosOnline. An electrical engineer by qualification, she worked for two years in the electrical domain before switching her professional genre. Following her childhood passion, she opted for a career in writin...

Read More

More from Satarupa


Post Recommendents

Red Dot Power plans to build 50 EV charging stations by 2019
Author: Ojaswita Kutepatil

Red Dot Power, the Singapore-based electricity retailer has recently announced that it will be investing around SGD 500,000 to install 50 electric vehicles charging stations in the nation by 2019. Reportedly, the firm wo...


Greencoat Renewables to purchase yet another wind farm in Ireland
Author: Dhananjay Punekar

Greencoat Renewables PLC, an Ireland based renewable-infrastructure firm, has decided to acquire Lisdowney, a 9.2 MW wind farm based in Co Kilkenny, for EUR 22.5 million. According to the

Nokia to opt between a sale or shut-down for its digital health unit
Author: Dhananjay Punekar

In a major turn of events witnessed across the digital health industry, Nokia has declared to have begun evaluating various alternatives for its online health activities. The firm’s decision apparently comes as a...